New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
08:41 EDTMDVNMedivation weakness a buying opportunity, says UBS
UBS said Medivation weakness from the PREVAIL presentation is a buying opportunity and said its Q4 urology survey indicates topline PREVAIL data will drive robust utilization. Shares are Buy rated with a $93 price target.
News For MDVN From The Last 14 Days
Check below for free stories on MDVN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
07:50 EDTMDVNPotential of Medivation Xtandi underappreciated, says Bernstein
Subscribe for More Information
07:37 EDTMDVNMedivation to host conference call
Conference call to discuss FDA approval of XTANDIŽ to be held on September 11 at 8:30 am. Webcast Link
07:11 EDTMDVNMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
16:41 EDTMDVNMedivation to resume trading at 4:50 pm ET
Subscribe for More Information
16:26 EDTMDVNMedivation receives $90M milestone payment after FDA approves XTANDI indication
Subscribe for More Information
15:16 EDTMDVNMedivation Xtandi efficacy supplement posted to FDA website
Subscribe for More Information
14:48 EDTMDVNMedivation trading halted, pending news
Subscribe for More Information
September 9, 2014
10:10 EDTMDVNOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
08:42 EDTMDVNMedivation upgraded at Bernstein
Subscribe for More Information
06:43 EDTMDVNMedivation upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use